Gideon Shapiro, PhD

Gideon Shapiro, a medicinal chemist by training started his 35-year career in big pharma at Sandoz-Novartis in Basel, Switzerland where he advanced in management of the CNS Alzheimer’s group department. He then transitioned his career into the biopharmaceutical CNS drug venture arena in management roles as VP of chemistry at Forum Pharmaceuticals and as CSO of Rugen. In this capacity he has been successful in inventing and advancing novel therapeutics through the early drug discovery and development process from compound optimization through IND and clinical development. Gideon is co-founder and CSO of Miralinc Pharma which is advancing the MRL-A102 HDAC6 inhibitor drug candidate with the aid of the Hereditary Neuropathy Foundation towards clinical trials in peripheral neuropathies and CMT hereditary.